newsroom.csl

Enhanced Influenza Vaccines Provide Essential Protection for Older Adults: CSL Seqirus Presents New Evidence Supporting Broader Adoption Across Europe

Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role ...
newsroom.csl

An Update on TAVNEOS® (avacopan) in the European Union: Our commitment to continued support for the ANCA Associated Vasculitis Community

Dear ANCA‑associated vasculitis community, We are writing to share an important update on TAVNEOS® (avacopan) in the European Union (EU). The European Medicines Agency’s (EMA’s) Committee for ...
newsroom.csl

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
newsroom.csl

Global Newsroom

Read more about An Update on TAVNEOS® (avacopan) in the European Union: Our commitment to continued support for the ANCA Associated Vasculitis Community Large cluster-randomized crossover study ...